Go Pro
→ A simple options setup that cuts through the noise (From TradeWins) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$31.62
$25.69
$10.83
▼
$41.14
$3.52B-0.133.68 million shs1.71 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%-7.27%+46.19%+108.16%+171.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$31.62
$25.69
$10.83
▼
$41.14
$3.52B-0.133.68 million shs1.71 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%-7.27%+46.19%+108.16%+171.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.5015.43% Upside

Current Analyst Ratings Breakdown

Latest AMLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$28.00 ➝ $52.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $42.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$34.00 ➝ $55.00
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$24.00 ➝ $30.00
8/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/3/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $26.00
7/20/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$21.00 ➝ $24.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M40.32N/AN/A$2.78 per share11.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)

Latest AMLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136111.42 million99.28 millionOptionable

Recent News About These Companies

First Light Asset Management LLC Has $54.30 Million Holdings in Amylyx Pharmaceuticals, Inc. $AMLX
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-light-asset-management-llc-has-5430-million-holdings-in-amylyx-pharmaceuticals-inc-amlx-2026-09-10/
Legal & General Group Plc Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-takes-position-in-amylyx-pharmaceuticals-inc-amlx-2026-09-08/
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-makes-new-679000-investment-in-amylyx-pharmaceuticals-inc-amlx-2026-09-07/
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Buy" from Analysts
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31007708
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Buy" by Analysts
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-amylyx-pharmaceuticals-inc-nasdaq-amlx-given-average-rating-of-buy-by-analysts-2026-09-07/
Corient Private Wealth LP Purchases New Holdings in Amylyx Pharmaceuticals, Inc. $AMLX
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-purchases-new-holdings-in-amylyx-pharmaceuticals-inc-amlx-2026-09-05/
274,435 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by Bank of New York Mellon Corp
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-274435-shares-in-amylyx-pharmaceuticals-inc-amlx-bought-by-bank-of-new-york-mellon-corp-2026-09-05/
1,053,015 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Alyeska Investment Group L.P.
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1053015-shares-in-amylyx-pharmaceuticals-inc-amlx-purchased-by-alyeska-investment-group-lp-2026-09-01/
Nantahala Capital Management LLC Buys Shares of 486,684 Amylyx Pharmaceuticals, Inc. $AMLX
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nantahala-capital-management-llc-buys-shares-of-486684-amylyx-pharmaceuticals-inc-amlx-2026-08-29/
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-acquires-new-stake-in-amylyx-pharmaceuticals-inc-amlx-2026-08-29/
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $57.00 at Guggenheim
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-amylyx-pharmaceuticals-nasdaq-amlx-price-target-raised-to-5700-at-guggenheim-2026-08-27/
Jupiter Topco LLC Makes New $94.01 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-makes-new-9401-million-investment-in-amylyx-pharmaceuticals-inc-amlx-2026-08-27/
Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-almitas-capital-llc-buys-shares-of-974881-amylyx-pharmaceuticals-inc-amlx-2026-08-27/
Elmind Capital LP Buys Shares of 112,000 Amylyx Pharmaceuticals, Inc. $AMLX
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-elmind-capital-lp-buys-shares-of-112000-amylyx-pharmaceuticals-inc-amlx-2026-08-26/
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 721,002 Amylyx Pharmaceuticals, Inc. $AMLX
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-purchases-shares-of-721002-amylyx-pharmaceuticals-inc-amlx-2026-08-26/
398,782 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by Parkman Healthcare Partners LLC
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-398782-shares-in-amylyx-pharmaceuticals-inc-amlx-bought-by-parkman-healthcare-partners-llc-2026-08-25/
Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-takes-position-in-amylyx-pharmaceuticals-inc-amlx-2026-08-24/
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
August 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/amylyx-amlx-faces-a-binary-phase-3-test-can-avexitide-rebuild-the-company-1811610/
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share
August 20, 2026  |  kalkinemedia.comK
Amylyx Pharmaceuticals Readies for Pivotal LUCIDITY Data
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AMLX/pressreleases/3729765/amylyx-pharmaceuticals-readies-for-pivotal-lucidity-data/
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/amylyx-phase-iii-avexitide-trial-cuts-severe-hypoglycemic-events-55-2026-08-18/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$31.62 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$31.62 0.00 (0.00%)
As of 09/11/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas